WO2025229618 - BLOOD GLUCOSE CONTROL WITH ENZYMATIC CYCLODEXTRIN INCLUSION COMPLEX FORMULATIONS
National phase entry is expected:
Publication Number
WO/2025/229618
Publication Date
06.11.2025
International Application No.
PCT/IB2025/054636
International Filing Date
02.05.2025
Title **
[English]
BLOOD GLUCOSE CONTROL WITH ENZYMATIC CYCLODEXTRIN INCLUSION COMPLEX FORMULATIONS
[French]
RÉGULATION DE LA GLYCÉMIE AVEC DES FORMULATIONS DE COMPLEXE D'INCLUSION DE CYCLODEXTRINE ENZYMATIQUE
Applicants **
CZAP RESEARCH AND DEVELOPMENT, LLC
Inventors
CZAP, Al
Priority Data
63/641,833
02.05.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2476 | |
| EPO | Filing, Examination, Granting | 18220 | |
| Japan | Filing, Examination, Granting | 2556 | |
| South Korea | Filing, Examination, Granting | 3001 | |
| USA | Filing, Examination, Granting | 5910 |
Total:
32,163
Contact Us
Abstract[English]
The invention provides oral cyclodextrin inclusion complex formulations in which inclusion complexes of oleuropein, humulene and trans-cinnamaldehyde are provided together with enzyme having a cyclodextrin-degrading activity capable of digesting cyclodextrins, so that upon delivery of the formulation to a target tissue the enzyme is activated and releases the oleuropein, humulene and trans-cinnamaldehyde from the cyclodextrins. These cyclodextrin inclusion complex formulations may be used for facilitating blood glucose homeostasis.[French]
L'invention concerne des formulations orales de complexe d'inclusion de cyclodextrine dans lesquelles des complexes d'inclusion d'oleuropéine, d'humulène et de trans-cinnamaldéhyde sont utilisés conjointement avec une enzyme ayant une activité de dégradation de cyclodextrine capable de digérer des cyclodextrines, de telle sorte que, lors de l'administration de la formulation à un tissu cible, l'enzyme est activée et libère l'oleuropéine, l'humulène et le trans-cinnamaldéhyde à partir des cyclodextrines. Ces formulations de complexes d'inclusion de cyclodextrine peuvent être utilisées pour permettre l'homéostasie du glucose sanguin.